Frost & Sullivan's recent analysis assesses which adoptive T-cell (CAR-T & TCR) therapies are in development and for which indicators, products launching in the next seven years, key players and their investment activities, cost implications, challenges to development, commercialization of adoptive T-cell therapies, and hurdles payors face relating to the high cost of speciality therapeutics.
For further information on this analysis, please visit: http://frost.ly/2ad
"CAR-T therapies are the newest cancer treatments transforming the treatment paradigms of previously difficult-to-treat cancers, with Juno, Gilead and Novartis jockeying for the best-in-class status. Adverse events such as reduced cytokine release syndrome (CRS) as well as decreased vein-to-vein times will contribute to product success. Ongoing research aims to develop allogenic therapies that would replace autologous, patient-specific ones for off-the-shelf therapies from unrelated donors—a treatment accessible to a greater number of patients," said Barbara Gilmore, Transformational Health Senior Industry Consultant at Frost & Sullivan.
To succeed in a highly competitive environment, Gilmore recommends companies tap into research advances in combination trials targeting more than one pathway to increase response rates over single targeted agents. A combination product produced by one company should be priced more competitively than targeted agents developed and marketed through a competitor's alliance.
Four strategic imperatives for growth include: 1. Focusing on identification of cancers with few existing treatments and where immuno-oncology products can better treat patients;2. Genetically engineered cell therapies providing real-time access to outcomes remission and survival data from in-progress clinical trials, enabling payers and policymakers to determine the potential value of therapies;3. Partnerships to invest in CAR-T and adoptive T-cell therapies to facilitate the advancements in the treatment of cancers and other diseases with immune cell affect potential; and4. Investing in supply chain applications related to cryopreservation, lentivirus creation, and allogenic product development to facilitate broader access to this type of therapy.
"Lack of manufacturing infrastructure, high pricing, and undefined reimbursement policies remain notable T-cell therapy hurdles; however, the ultimate goal of increasing overall survival is not insurmountable," observed Gilmore.
Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022 is part of Frost & Sullivan's Transformational Health Growth Partnership Services program.
About Frost & SullivanFrost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022MC55_52
Contact:Mariana FernandezCorporate Communications – North AmericaP: +54 11 4778 3540F: +54 11 4777 0071E: [email protected]
http://ww2.frost.comtwitter: @FS_HealthcareLinkedIn: Transform Health
View original content:http://www.prnewswire.com/news-releases/immuno-oncology-therapeutics-market-to-reach-39-billion-by-2022-finds-frost--sullivan-300615844.html
SOURCE Frost & Sullivan
